Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.54 |
| ▸ | ADH1A | P07327 | 4/20 | 0.54 |
| ▸ | ADH7 | P40394 | 3/20 | 0.54 |
| ▸ | ADH1C | P00326 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ADH4 | P08319 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24798454 | 1.00 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL20845975 | 1.00 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL19903786 | 1.00 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL25699155 | 1.00 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL18735621 | 1.00 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3465685 | 0.98 | — | — | |
| SCHEMBL22419958 | 0.86 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL21657438 | 0.86 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL9574479 | 0.86 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL10940490 | 0.85 | ADH1B (0.48) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| WO-2024114528-A9 | COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024114528-A1 | COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | ADH1B 2445/4885ADH1A 692/4885ADH7 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.